Obesidade, diabete melito e osteoporose by PAULA, Francisco J. A. de & ROSEN, Clifford J.
review
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
Arq Bras Endocrinol Metab. 2010;54/2150
1 Departamento de Medicina 
Interna, Faculdade de Medicina 
de Ribeirão Preto, Universidade 
de São Paulo (FMRP-USP), 
Ribeirão Preto, SP, Brasil
 2 Maine Medical Center 
Research Institute, Scarborough, 
ME, Estados Unidos
Correspondence to:
Clifford J. Rosen
Maine Medical Center Research 
Institute, 81
Research Drive
04074-7205 − Scarborough, ME
Estados Unidos
rosenc@mmc.org
Received on Nov/16/2009
Accepted on Jan/28/2010
Obesity, diabetes mellitus and 
last but not least, osteoporosis
Obesidade, diabete melito e osteoporose
Francisco J. A. de Paula1,2, Clifford J. Rosen2
Summary
Knowledge about the influence of bone on intermediary metabolism corresponds to a deve-
loping area that has gained prominence. The old concept of bone and adipose tissues as inert 
metabolic tissues, with minor contributions to metabolic adaptations has been reconsidered in 
light of findings that bone is involved in the development of insulin sensitivity. Similarly adipo-
se tissue exerts important influences on bone mass development and maintenance. Moreover, 
the use of drugs in the treatment of metabolic disorders such as diabetes mellitus can impact 
bone metabolism. These networks linking osteoporosis to obesity and diabetes mellitus have 
reinvigorated investigations in the pathophysiology of osteoporosis. The present review exami-
nes this aspect and calls attention to health care providers and potential treatments of skeletal 
disorder. Arq Bras Endocrinol Metab. 2010;54(2):150-7
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Sumário
O estudo sobre a influência do tecido ósseo no metabolismo intermediário corresponde a uma 
área em desenvolvimento que tem ganho recente destaque. O conceito prévio de que os te-
cidos ósseo e adiposo seriam metabolicamente inativos foi reconsiderado à luz de estudos 
que mostram que metabólitos ósseos podem influenciar a sensibilidade à insulina. Da mesma 
forma, o tecido adiposo exerce influência importante no desenvolvimento e na manutenção 
da massa óssea. Além disso, o uso de drogas no tratamento de doenças metabólicas como o 
diabetes melito pode afetar o metabolismo ósseo. A rede de conexões existentes que ligam a 
osteoporose à obesidade e ao diabetes melito tem revigorado investigações sobre a fisiopato-
logia da osteoporose. A presente revisão analisa esse aspecto e destaca a necessidade de aten-
ção para esses pontos por parte de serviços de saúde voltados para o atendimento de diabetes 
melito e da obesidade quanto ao potencial impacto sobre o tecido ósseo. Arq Bras Endocrinol Metab. 
2010;54(2):150-7
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introDuction
Human being image has changed significantly in the last fifty years due to the evolving tendency 
to increase in body weight. Obesity, the metabolic di-
sorder characterized by excessive fat storage reflects the 
imbalance between energy intake and expenditure. The 
epidemic characteristic of the disturbance can be verified 
by the impressive 100% increase in the rate of obese pe-
ople in the USA in data from the period of 1976-1980 
(15% of adult population) toward 1999-2002 (31% of 
adult population) (1). Data obtained in South America 
were similar since in Brazil the increase in obesity rate 
was 92% in men and 63% in women from 1975 toward 
1989 (2). 
Diabetes mellitus (DM) is a heterogeneous metabolic 
disorder characterized by the presence of hyperglyce-
mia. Recent data indicate that 12.9% of the adult U.S. 
population aged ≥ 20 years have DM, of which 39.8% is 
undiagnosed (3). A national survey conducted in Bra-
zil two decades ago showed a DM prevalence of 7.6%, 
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
151Arq Bras Endocrinol Metab. 2010;54/2
Bone and energetic metabolism
which was similar to other Western countries for the 
same period (4). Type 2 DM (T2DM) comprises 90% 
of all cases of DM syndrome. A major risk factor for 
developing T2DM is excessive adiposity.
Bone loss and degenerative changes of bone charac-
teristics are a progressive process occurring after matu-
rity. Therefore, the increase in life expectancy places os-
teoporosis as one of the major health public problems 
in the world. Among US population aged more than 
50 years, 10 million have osteoporosis (5). In a recent 
Brazilian population-based study the prevalence of fra-
gility fracture in women and men aged higher than 40 
years were 15.1 and 12.8%, respectively (6). 
Insulin resistance, the central metabolic disturbance 
associated with fat accumulation, is linked to metabolic 
(i.e. increased free fat acids and hypertriglyceridemia), 
endocrine (i.e. increased glucocorticoid and andro-
gens) and pro-inflammatory (i.e. cytokines and tumor 
necrosis factor) alterations. During the last decade, the 
role of adipose tissue as an exclusive site of energy stor-
age has shifted to one that is an endocrine source of ac-
tive modulators of insulin sensitivity such as leptin, adi-
ponectin, resistin and cytokines. Furthermore, visceral 
adipose tissue has an increased lipolytic activity and 
releases FFA swiftly to the liver and pancreas, thereby 
provoking lipotoxicity. Insulin, as well as those adipose 
tissue factors, also influences bone remodeling. 
Recently, investigators have identified polypeptides 
such as osteocalcin and osteopontin, which can also 
modulate insulin sensitivity (7). These new networks 
link metabolic disturbances to osteoporosis in a new 
bidirectional pattern. The clinical impact of this associa-
tion cannot be currently predicted due to the heteroge-
neity of each disorder. However, it cannot be neglected, 
particularly since one of the most promising groups of 
drugs to treat diabetes (thiazolidinediones) can induce 
bone fragility. In the present review we discuss several 
aspects of the relationship between hard and soft tissues. 
The clinical association between osteoporosis, obesity 
and DM and its mechanisms are contemplated, our 
principal focus is to call attention to the potential recip-
rocal relationship of these common diseases.
oSteoporoSiS anD obeSity
Previous studies showed that body weight correlates 
positively with bone mineral density. In addition, rapid 
weight loss by severely obese individuals can induce 
bone loss, as high as 10 percent in the femoral neck, 
one year after bariatric surgery (8). Notwithstanding 
the evidence suggesting a beneficial effect of adipose 
tissue on bone maintenance, other data argue against 
this effect. A large population-based study in China did 
not verify positive correlation between bone mass and 
fat mass (9). Similar results were obtained in adoles-
cents and young adults of both sexes (10).
Bone mineral density (BMD) alone, although cur-
rently considered the strongest single factor correlated 
to risk of fracture, does not permit a comprehensive 
recognition of fracture risk. There are several other in-
dependent factors contributing to fracture risk (age, 
glucocorticoid therapy, previous fracture, smoking, al-
cohol abuse, and rheumatoid arthritis). Also, low body 
mass index (BMI) only affects the risk of fracture in-
dependently of BMD in the case of hip fracture, most 
likely through an association with frailty and increased 
risk of fall (11). 
Population-based studies revealed that less than a 
half of the people with a sustained fragility fracture have 
BMD values below the threshold established by the 
WHO report as osteoporosis (12-13). Consequently, 
the majority of fractures that occur in individuals is clas-
sified at most as osteopenic. Also, a significant num-
ber of individuals have osteoporotic fractures despite a 
normal T-Score (12-13). In addition to revealing the 
limitations of BMD measurements these data highlight 
the important contribution of independent risk factors 
to fracture risk.
Evidence showing an association between obesity 
and fracture were acquired in a pediatric clinical inves-
tigation. The study exhibited higher forearm fracture 
incidence in obese children compared with normal 
weight, age-matched individuals. Recently, more com-
pelling data was obtained by Premaor and cols. (14), 
when they audited the profile of patients aged less than 
75 years, attending the Liason Fracture Service, in the 
United Kingdom, with a fragility fracture (14). Ap-
proximately, 40% of this group had normal BMD and 
more than 50% were obese or morbidly obese patients. 
Within the obese and morbid obese patient subgroups 
80% and 89% had normal value of BMD T-Score of 
total hip. Thus, these results confirm the tenet that 
obesity has a protective role on BMD, but at the same 
time suggest the occurrence of high fracture risk in this 
population (Figure 1).
Furthermore, there are several clinical conditions in 
which weight gain occurs with parallel bone loss (15). 
The physiological changes associated with menopause in-
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Bone mass loss
↓  Mechanical effect
↓  Reduced insulin, IGF-1, estrogen, 
adiponectin, ghrelim
↓  Calcium absorption
Protective effect on bone mass
↑  Mechanical effect
↑  Insulin, leptin, estrogen
↑  Calcium absorption
OBESITY
WEIGHT LOSS 
INDUCED BY RYGB
Increased Fall Risk
Disorder of bone quality
Mineralization disorder
Bone mass loss
Increased fall risk
Disorder of bone quality (?)
Increased fracture risk
+
Figure 1. (A) Pathophysiology of the increased fracture risk in obesity. (B) Pathophysiology of bone loss and of the increased fracture risk associated to 
weight loss after bariatric surgery.
a b
clude fat accumulation on one side and bone catabo lism 
on the other. The same pattern is observed in hypercor-
tisolism. Another circumstance emerged with the use of 
activators of the PPARγ (thiazolidinediones) for the treat-
ment of T2DM. At the same time patients using these 
drugs experience decrease in blood glucose levels and 
gain weight due to the increase in peripheral adipose tis-
sue. Clinical investigations showed bone loss and higher 
rates of fracture in diabetics using rosiglitazone compared 
to others on metformin or glyburide (16). Coincidentally 
with bone loss associated with glucocorticoids and ag-
ing, rosiglitazone enriches bone marrow fat while bone 
volume is reduced. Thus, like insulin resistance which has 
visceral fat as a marker; fat allocation in bone marrow is 
an indicator of osteoporosis. While the waist to hip rate 
is a surrogate identifier of obesity linked to insulin resis-
tance, currently there is no clinical means to distinguish 
the obese patient associated with osteoporosis.
osteoporosis and obesity treatments
Independent of its influence on skeleton, obesity is as-
sociated with several major health problems and has a 
strong psychological impact. Hypertension, DM and 
dyslipidemia are all closely associated to obesity and 
together increase significantly the risk of cardiovascu-
lar disease (17). Obese patients also have increased risk 
to develop breast, colon, prostrate and endometrial 
cancer (17). Moderate weight loss is an efficient way 
to prevent the risk to develop DM in overweight and 
obese individuals, while drastic weight loss ameliorates 
the expectancy of life of severely obese patients. Thus, 
weight loss is pursued by patients and encouraged by 
physicians to decrease the risk of cardiovascular disease 
and related disorders. However, the quality of life of a 
considerable number of these patients can be affected, 
since the consequences of weight loss on body compo-
sition is not limited to adipose tissue. Bone tissue seems 
exquisitely sensitive to decrements in body weight. 
Previous studies have shown that even 10% weight 
loss can induce about 2% bone loss (18,19). The impact 
can be higher in individuals exposed to more intense 
and rapid weight loss (20) compared to moderate dec-
rement in weight and for longer periods (21).
Unfortunately, the clinical management of obesity 
based on changes in life style habits has yielded frus-
trating results on a long-term basis. This is largely due 
to the slow process of weight loss and to the need for 
strong involvement and effort on the part of the patient 
that should last throughout life. The need to develop 
therapeutic options whose efficacy is less dependent on 
the patient’s determination and the challenging effort 
to change habits has favored the use of gastric reduction 
surgery as a desirable alternative. Weight loss evolves 
rapidly, and currently bariatric surgery has increasingly 
become recognized as a highly effective alternative for 
achieving major weight reduction for obese patients. 
A large prospective cohort study [Swedish Obese Sub-
jects (SOS) study] found that weight loss was still ap-
parent 10 years following surgery, whereas patients re-
ceiving conventional treatment had gained weight (22). 
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
153Arq Bras Endocrinol Metab. 2010;54/2
Bone and energetic metabolism
The Roux-en-Y gastric bypass (RYGB) procedure 
combines restriction and malabsorption techniques, 
creating both a small gastric pouch and a deviation of a 
segment of the small intestine. Presently, RYGB is the 
most frequent and efficient surgery option to treat se-
vere obesity and will be the only one we will discuss in 
the present review. 
Patients may be at risk of postgastrectomy bone 
disease. Metabolic bone disease is a well-documented 
long-term complication of obesity surgery. It is often 
undiagnosed, or misdiagnosed, because of lack of phy-
sician and patient awareness. Abnormalities in calcium 
and vitamin D metabolism begin shortly after gastro-
intestinal bypass operations; however, clinical and bio-
chemical evidence of metabolic bone disease may not 
be detected until many years later. RYGB can potential-
ly be associated to two metabolic bone disorders osteo-
malacia and osteoporosis. Isolated cases of osteomalacia 
in patients submitted to gastric bypass for morbid obe-
sity treatment have been published in the last few years, 
resembling old cases of osteomalacia after gastric re-
section for management of peptic ulcer (23,24). While 
severe osteomalacia seems a latter and less frequent 
complication, bone loss appears to be an early effect on 
almost all patients submitted to RYGB (Figure 1).
osteometabolic changes after roux-en-y gastric bypass
Vitamin D has an important role in calcium absorption. 
Estrogen levels, dietary intake, age and body weight 
also influence calcium absorption. True fractional cal-
cium absorption can be approximately 10% higher in se-
verely obese patients compared to overweight individu-
als, most likely as a result of higher estrogen levels and 
increased gastrointestinal mucosal surface (25). Thus, 
RYGB has significant impact on calcium and vitamin 
D metabolism. Diet restriction reduces the exogenous 
load of calcium and vitamin D and decreases intake of 
macronutrients that positively affect their absorption. In 
RYGB, the proximal jejunum is bypassed, excluding an 
important site of calcium absorption, which contributes 
to the decreased calcium load. Additionally, the reduc-
tion in food intake leads to increased release of cortisol 
and decrease in IGF-I serum levels, both adaptations 
potentially impair calcium absorption (25) (Figure 1).
Adipose tissue shrinkage modifies the adipocyte se-
cretion profile. Whereas leptin declines, adiponectin 
increases after weight loss, though the impact of these 
changes on bone remodeling is still to be understood. 
Leptin induces bone loss indirectly by the central stim-
ulation of the sympathetic system, but acts directly on 
osteoblasts, stimulating bone formation. Conflicting 
results have been obtained on clinical investigation 
about bone effects of adiponectin, suggesting neutral, 
positive or negative association to BMD. Estrogens, 
IGF-I and insulin fall after weight loss. Gastrointestinal 
hormones are other variables to be considered in the 
global evaluation of the weight loss impact on bone. 
Ghrelin, a stomach-derived peptide, increases during 
food deprivation to stimulate appetite. In contrast, 
weight loss due to gastric bypass produces significant 
reduction of ghrelin levels (25). Previous data have 
shown that ghrelin stimulates osteoblast proliferation 
and differentiation. Glucagon-like peptide-2 (GLP-2), 
an enteroendocrine L-cell derived hormone, is an in-
hibitor of gastric emptying. GLP-2 also decreases bone 
resorption (26) and has positive effect on bone miner-
alization (27). Overall, the nutritional, metabolic and 
hormonal changes produced by rapid weight loss favor 
bone resorption. Considering that obesity can be asso-
ciated with fracture and that obesity treatment also can 
damage skeleton, it is reasonable to conclude that the 
primary target should be obesity prevention.
bone mineral density evaluation in obese patients
The evaluation of BMD in obese patients by DXA is 
limited by the capacity of equipment to support and to 
measure individuals weighing more than 115-160 kg, 
depending on the manufacturer. New machines can ac-
commodate individuals of up to 180 kg, but it is still 
insufficient to satisfy the current profile of obesity. The 
follow up of total body BMD during weight loss is con-
founded by variables such as fat density and distribu-
tion. 
Peripheral BMD is the alternative suitable to evalu-
ate bone mass in obese patients. Peripheral DXA mea-
surements at phalanges and proximal/distal forearm 
have been shown in studies to correlate directly with 
BMD measurements of the spine and hip by central 
DXA. Quantitative ultrasound seems to be less closely 
correlated with hip and spine BMD by DXA.
management after roux-en-y gastric bypass
 Follow up includes careful examination to detect sub-
clinical fracture. Patient stature should be measured be-
fore and at regular intervals after surgery. If necessary, 
vertebral fracture might be assessed by lateral spine ra-
diograph. 
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Figure 2. Pathophysiology of the increased fracture risk in type 1 and type 2 diabetes mellitus.
Low weight ↓ IGF-I
↓ Insulin
↓ Estrogen
Low bone mass Equilibrium
disorders
↑ Fracture risk
Microdamage
accumulation
?
↑ proteolysis
↓ Muscle strength
Oculopathy
neuropathy
Protein
glycation
Obesity
Diabetes mellitus
Type 1 Type 1-Type 2 Type 2
Patients undergoing RYBG should be screened for 
osteoporosis with bone density measurement. Labora-
tory evaluation includes calcium, albumin, magnesium, 
PTH and 25(OH)D.
Operated patients should be encouraged to perform 
regular weight-bearing physical exercise. Recent data 
suggest increased fall risk in post-operative bariatric 
surgery patients (28). Thus, mechanical risks for falls 
should be addressed and physical activity is part of the 
strategy to reduce fracture risk.
Calcium and vitamin D supplementation should 
be prescribed in all bariatric patients. One should con-
sider slightly higher doses than RDI recommendations: 
1,500 mg calcium and 2000 UI vitamin D. Check 
25(OH)D serum levels every three months to ensure 
adequate levels. One should consider pharmacological 
treatment in patients if BMD is below -1.5. In patients 
with severe malabsorption parenteral administration 
may be more convenient.
Diabetes Mellitus anD oSteoporoSiS
The term heterogeneous is correct in defining diabetes 
mellitus (DM) due to the large spectrum of variation 
in its etiopathogenesis and clinical manifestations. Al-
most certainly, the only rule valid to all diabetic pa-
tients is the tendency to hyperglycemia. Osteoporosis 
can be added to the large list of disorders associated to 
DM whose mechanistic association and magnitude of 
clinical impact have been hard to clarify. When BMD is 
used as surrogate indicator of osteoporosis, most data 
suggest that type 1 diabetes mellitus (T1DM) is linked 
to osteoporosis. Also, results from the Nord-Trondelag 
Health Survey from Norway showed a significant in-
crease in hip fracture rates among female type 1 dia-
betic patients (relative risk 6.9, confidence interval 2.2-
21.6) compared to nondiabetic female patients (29). 
However, the results are quite undefined in relation to 
T2DM, existing indications of bone loss, bone mainte-
nance and protective effects on bone.
The differences between T1 and T2 DM are not 
surprising in view of that many unfavorable factors to 
bone present in the former are usually absent in the 
latter (Figure 2). Low body weight, hypoinsulinemia 
and low serum levels of IGF-I are common clinical and 
biochemical features of T1DM, which are not encom-
passed within T2DM (30). Poor glucose control is an 
etiological factor for the microangiopathic complica-
tions that develop in all DM types. Although there are 
data suggesting a higher bone loss rate in chronically 
hyperglycemic patients, hyperglycemia is not clearly 
linked to low bone mass in case of T2DM (31). How-
ever, bone mass is not the sole determinant of bone 
strength; other components (i.e., material properties, 
microdamage accumulation and bone microarchitec-
ture) are important for bone quality and have criti-
cal role on bone propensity to fracture. Schwartz and 
cols. (31), in a large prospective study in older women 
obtained from the Study of Osteoporotic Fractures, 
confirmed that women with T2DM experience higher 
fracture rates in regions of the hip, humerus and foot 
than do nondiabetic women (31). DM affects protein 
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metabolism and recent studies have shown impairment 
of muscle function and balance in diabetic patients. 
Therefore, diabetic patients have a greater susceptibil-
ity to fall and bone microdamage. Additionally, a wide 
range of pathogenic pathways have been proposed that 
underlie bone quality dysfunction in osteoporosis sec-
ondary to DM. Protein glycation is a common post-
translational modification of proteins induced by the 
spontaneous condensation of glucose and metabolic in-
termediates (e.g. triose phosphate, glyoxal and methy-
glyoxal) with free amino groups in lysine or arginine 
residues. This process leads to an irreversible formation 
of advanced glycation end products (AGE) from an ar-
ray of precursor molecules (32). Alfa-oxaloaldehydes 
such as glyoxal, methylglyoxal (MGO) and 3-deoxy-
glucosone occur at high levels in diabetic plasma or are 
significantly elevated in cells exposed to high glucose 
concentrations (32). They can react directly with pro-
tein to yield intracellular and extracellular AGEs, which 
have been shown to have significant pathogenic effects 
in cells and tissues (33,34). Collagen cross-linking, a 
major post-translational modification of collagen, plays 
important roles in the biological and biomechanical 
features of bone. Collagen cross-links can be divided 
into lysyl hydroxylase and lysyl oxidase-mediated en-
zymatic immature divalent cross-links, mature trivalent 
pyridinoline and pyrrole cross-links and glycation- or 
oxidation-induced non-enzymatic cross-links (ad-
vanced glycation end products) such as glucosepane 
and pentosidine. These types of cross-links differ in the 
mechanism of their formation and function, determin-
ing differences in the mineralization process as well as 
in the bone tendency to microdamage. Pentosidine is 
one of the well-known AGEs, and its concentration 
in cortical and trabecular bone is negatively associated 
with bone strength. Previous studies showed that pa-
tients with femoral neck fractures had higher concen-
trations of pentosidine in cortical (35) and cancellous 
bone (36) than in controls. In vitro, high glucose and 
AGEs synergistically inhibit the mineralization activity 
of MC3T3-E1 cells through glucose-induced increase 
in the receptor for AGE (RAGE) (37). Diabetic patients 
have significantly higher levels of serum pentosidine 
than control individuals. Furthermore, in a recent clini-
cal study, Yamamoto and cols. (38) observed in a small 
group of patients that pentosidine serum levels were 
positively and significantly associated with the presence 
of vertebral fractures in postmenopausal women with 
DM and that this association was independent of BMD. 
Thus, there is a dichotomy between BMD and frac-
ture risk in type 2 diabetic patients. Obesity, as discussed 
above, and protein glycation are two contributing fac-
tors that increase the susceptibility to fracture in T2DM 
that are not reflected in bone mass measurement.
Diabetes mellitus treatment and osteoporosis
Results obtained in the DCCT and UKPDS studies 
showed that plasma glucose levels are directly implicat-
ed in the development of diabetic complications. Low 
plasma glucose levels were then pursued as a surrogate 
parameter for the most important objective in the treat-
ment of DM, the prevention of chronic micro and mac-
roangiopathic disorders.
Thiazolidenediones (TZD) were introduced as 
powerful glucose lowering agents that could reduce 
complications in T2DM. The first of these drugs, tro-
glitazone, was withdrawn from the market because of 
hepatotoxicity. Rosiglitazone and pioglitazone, two 
other TZDs, are currently approved to treat T2DM 
and may potentially be helpful in other insulin-resis-
tant disorders (39). The efficiency of rosiglitazone to 
maintain DM under metabolic control is greater than 
glyburide and metformin (16). However, there may be 
an increased risk of cardiovascular disease in patients 
treated with rosiglitazone. Additionally, experimental 
and clinical evidence indicates that TZD use is asso-
ciated with adverse effects on the skeleton, mainly in 
postmenopausal women with T2DM.
Osteoblasts and marrow adipocytes are derived from 
a common multipotential stem cell (MSC) progenitor. 
It has been hypothesized that the close relationship be-
tween these lineages underlies the reciprocal relationship 
between increased adipocytes and decreased bone for-
mation that occurs during aging and with TZD therapy.
MSC fate is determined by expression and/or acti-
vation of specific transcription factors [i.e., Runx2 and 
Osterix in the case of osteoblasts and CCAAT enhancer 
binding protein β and peroxisome proliferator-activat-
ed receptor γ (PPARγ) in the case of adipocyte]. The 
transcriptional activity of PPARγ is induced by endoge-
nous ligands such as prostaglandin J2 and oxidized fatty 
acids as well as by exogenous ligands such as the TZDs.
TZDs provoke bone loss in rats (40) and mice (41). 
BMD decreases in humans can be observed as early as 14 
weeks after the treatment with rosiglitazone. Suppression 
in the production of biochemical markers of bone forma-
tion has also been observed after four weeks of treatment 
with rosiglitazone. The cellular basis of this skeletal re-
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sponse relates to the suppression of key osteoblastogenic 
transcription factors Runx2 and Osterix (41).
The accumulating evidences of TZD-induced skel-
etal toxicity prompted the pharmaceutical companies 
marketing these agents to analyze adverse event data 
collected during the performance of phase III trials. For 
example, the ADOPT study, a 4-year investigation de-
signed to compared rosiglitazone, metformin and gly-
buride in the maintenance of glycemic control, showed 
that women, not men, on rosiglitazone had a higher in-
cidence of appendicular fractures than women on met-
formin or glyburide. As this event was not a pre-specified 
issue, vertebral fracture data are not available. Although 
appendicular fracture is not the most typical osteopo-
rotic fracture it seems to be more prevalent in diabetic 
populations. Data review was also performed on clinical 
trials of pioglitazone. Increased limb fractures were also 
observed in patients treated with this TZD, and once 
again this finding was only in female diabetic patients.
management of diabetic patients in 
thiazolidenedione therapy
Health care providers need to be aware of the possibil-
ity of increased bone loss and fracture risk associated 
with TZD use. It is recommended that clinical fracture 
risk in patients be determined before initiation of TZD 
therapy. For postmenopausal women with DM, par-
ticularly those on TZD therapy, screening BMD may 
be useful. Osteoporosis therapy should be initiated in 
those women whose bone density and other risk factors 
place them at an increased risk for fracture.
concluSion
Recent studies have shown that there is functional plas-
ticity in bone, and that it is far greater than originally 
appreciated. Bone remodeling, the mechanism neces-
sary to maintain bone strength, is sensitive to metabolic 
disarrangements such as DM and obesity. Surprisingly, 
recent studies have indicated that bone cells contribute 
to metabolic activity by the production of peptides such 
as osteocalcin that impacts insulin sensitivity and energy 
metabolism. These new networks will have implications 
at the bed side and are certain to be incorporated into 
newer strategies to treat both osteoporosis and diabetes.
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